

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 June 2023 (08.06.2023)



(10) International Publication Number
WO 2023/100070 A1

(51) International Patent Classification:

A61K 31/4196 (2006.01) A61K 31/565 (2006.01)
A61K 31/506 (2006.01) A61K 45/06 (2006.01)
A61K 31/519 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2022/061525

(22) International Filing Date:

29 November 2022 (29.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/285,320 02 December 2021 (02.12.2021) US
63/382,346 04 November 2022 (04.11.2022) US
63/383,969 16 November 2022 (16.11.2022) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **LIN, Tun Tun**; c/o Pfizer Inc., 10777 Science
Center Drive, San Diego, California 92121 (US). **YANG,
Jing**; c/o Pfizer Inc., 10777 Science Center Drive, San
Diego, California 92121 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route
206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack,
New Jersey 07977 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: CDK4 INHIBITOR FOR THE TREATMENT OF CANCER



(57) Abstract: The disclosure provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060. The disclosure also provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060 and an endocrine therapy agent.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*